Compare ONL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | CNTB |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 135.7M |
| IPO Year | 2021 | 2020 |
| Metric | ONL | CNTB |
|---|---|---|
| Price | $2.62 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $8.67 |
| AVG Volume (30 Days) | 187.4K | ★ 487.0K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,647,000.00 | $64,000.00 |
| Revenue This Year | $4.10 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.92 | $1.23 |
| 52 Week High | $3.04 | $3.82 |
| Indicator | ONL | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 40.68 |
| Support Level | $2.62 | $2.03 |
| Resistance Level | $2.71 | $2.75 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 36.36 | 4.88 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.